N-叔丁氧羰基-N'-芴甲氧羰基-D-2,3-二氨基丙酸 | 131570-56-4

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 其他氨基酸衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: N-叔丁氧羰基-N'-芴甲氧羰基-D-2,3-二氨基丙酸
• 中文别名: (R)-2-(Boc-氨基)-3-(Fmoc-氨基)丙酸；N-叔丁氧羰基-N''-芴甲氧羰基-D-2,3-二氨基丙酸；壬烯酸甲酯
• 英文名称: Boc-D-Dap(Fmoc)-OH
• 英文别名: (2R)-3-(9H-fluoren-9-ylmethoxycarbonylamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
• CAS: 131570-56-4
• 化学式: C₂₃H₂₆N₂O₆
• 分子量: 426.469
• InChiKey: MVWPBNQGEGBGRF-LJQANCHMSA-N

物化性质

• 沸点：
  652.5±55.0 °C(Predicted)
• 密度：
  1.263±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  密封，在温室中保存

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Boc-d-dap(fmoc)-oh
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Boc-d-dap(fmoc)-oh
CAS number: 131570-56-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C23H26N2O6
Molecular weight: 426.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-叔丁氧羰基-N'-芴甲氧羰基-D-2,3-二氨基丙酸 在 TEA 、 五氟苯基二苯基磷酸酯 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 1-羟基苯并三唑 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 Boc-D-Dap(1)-Asn-bAla(2R-OBz)-Trp(5-Br)-(1)
  参考文献：
  名称：

  有关环酰胺A绝对构型的研究：4（R），11（R）-环酰胺A的全合成

  摘要：

  的芴基甲基酯的偶合3（的（R = FM）小号）-5- bromotryptophan用N α -BOC-（小号）-Asn-O苯甲酰基（- [R）-ise 9产生了三肽10。在BOC基团的裂解10，接着用N个耦合α -BOC-N β -Fmoc-（[R）-2-3二氨基丙酸，得到四肽11将其转化成环肽12。在BOC的裂解12接着与甘氨酸偶联衍生的侧链14产生了，除去苯甲酰基团后，以4（R），11（R）-环酰胺A（2）与天然环酰胺A（1）不同，表明1具有4（S），7（S），11（S），14（S）构型。

  DOI：

  10.1016/s0040-4039(98)02016-4
• 作为产物：
  描述：

  Boc-D-天冬酰胺 在 碘苯二乙酸 作用下， 以 丙醇 、 乙酸甲酯 、 水 、 丙酮 为溶剂， 反应 3.0h， 生成 N-叔丁氧羰基-N'-芴甲氧羰基-D-2,3-二氨基丙酸
  参考文献：
  名称：

  有关环酰胺A绝对构型的研究：4（R），11（R）-环酰胺A的全合成

  摘要：

  的芴基甲基酯的偶合3（的（R = FM）小号）-5- bromotryptophan用N α -BOC-（小号）-Asn-O苯甲酰基（- [R）-ise 9产生了三肽10。在BOC基团的裂解10，接着用N个耦合α -BOC-N β -Fmoc-（[R）-2-3二氨基丙酸，得到四肽11将其转化成环肽12。在BOC的裂解12接着与甘氨酸偶联衍生的侧链14产生了，除去苯甲酰基团后，以4（R），11（R）-环酰胺A（2）与天然环酰胺A（1）不同，表明1具有4（S），7（S），11（S），14（S）构型。

  DOI：

  10.1016/s0040-4039(98)02016-4

文献信息

• Efficient Solid-Phase Synthesis of Peptide-Based Phosphine Ligands: Towards Combinatorial Libraries of Selective Transition Metal Catalysts
  作者：Christian A. Christensen、Morten Meldal

  DOI：10.1002/chem.200500105

  日期：2005.7.4

  tedious protection/deprotection of the phosphine moieties during the synthesis of the ligands. The extensive use of commercial building blocks and standard SPPS makes this methodology well suited for the generation of solid-phase combinatorial libraries of novel ligands. Furthermore, it is possible to generate several different phosphine ligand libraries for every peptide scaffold library synthesised, by

  已经开发了用于固相合成基于肽的膦配体的新方法。在标准固相肽合成（SPPS）中，使用可商购的Fmoc保护的氨基酸和易于获得的Fmoc保护的氨基醛合成具有伯胺或仲胺的固相支持的肽支架，以进行还原烷基化。在与钯（II）络合之前，通过游离胺的膦甲基化将膦部分引入作为最终的固相合成步骤，从而避免了在配体合成过程中对膦部分进行繁琐的保护/脱保护。商业构件和标准SPPS的广泛使用使该方法非常适合于生成新型配体的固相组合文库。此外，通过用不同的膦部分官能化支架文库，可以为每个合成的肽支架文库生成几个不同的膦配体文库。合成的配体通过常规的（31）P NMR光谱在固体载体上进行表征，并通过HPLC，（1）H NMR，（31）P NMR和高分辨率ESMS从载体上裂解为膦氧化物。由树脂结合的配体生成钯（II）烯丙基络合物，并证明其催化性能，进行了钯催化的不对称烯丙基取代反应。对于所选的催化剂和底物组合，获得了良好
• [EN] SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME<br/>[FR] COMPOSÉS ANTAGONISTES DU RÉCEPTEUR DE LA SOMATOSTATINE ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：CDRD VENTURES INC

  公开号：WO2017136943A1

  公开（公告）日：2017-08-17

  The present invention is directed to somatostatin receptor antagonist compounds having the structure of Formula I, compositions comprising the same, and methods of using such compounds and compositions. The compounds may be useful in the prevention or treatment of hypoglycemia.

  本发明涉及具有式I结构的生长抑素受体拮抗剂化合物，包含该化合物的组合物，以及使用该化合物和组合物的方法。这些化合物可能有助于预防或治疗低血糖。
• [EN] ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT COMPRENANT DES AGONISTES DE STING
  申请人：MERSANA THERAPEUTICS INC

  公开号：WO2021202984A1

  公开（公告）日：2021-10-07

  The present disclosure provides scaffolds and antibody-drug conjugates (ADCs) comprising a stimulator of interferon genes (STING). The present disclosure also provides uses of the ADCs in treatment, e.g., treatment of cancer.

  本公开提供了包含干扰素基因刺激剂（STING）的支架和抗体药物偶联物（ADCs）。本公开还提供了ADCs在治疗中的用途，例如癌症治疗。
• NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF
  申请人：Boyd A. Vincent

  公开号：US20070021434A1

  公开（公告）日：2007-01-25

  The present dislcosure provides amide-based, non-nucleoside compounds having antiviral activity against Hepacivirus, such as hepatitis C virus (HCV), methods and intermediates for synthesizing such compounds, and methods of using the compounds in a variety of contexts, including in the treatment and prevention of viral infections. The present dislcosure also provides methods for identifying amide-based, non-nucleoside compounds having antiviral activity.

  本公开提供了基于酰胺的非核苷类化合物，具有抗Hepacivirus活性，例如丙型肝炎病毒（HCV），合成这类化合物的方法和中间体，以及在各种情境中使用这些化合物的方法，包括在治疗和预防病毒感染中的应用。本公开还提供了识别具有抗病毒活性的基于酰胺的非核苷类化合物的方法。
• COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE
  申请人：Cameron Dale Russell

  公开号：US20080171783A1

  公开（公告）日：2008-07-17

  The present disclosure provides amide-based, non-nucleoside compounds having an inhibitory activity against endogenous polymerases, such as polymerase alpha and polymerase gamma. This disclosure further provides uses of treating hyperproliferative diseases or disorders, such as benign or malignant neoplasms, and more specifically cancers that are sensitive to inhibition of polymerase alpha and polymerase gamma.

  本公开提供了基于酰胺的非核苷类化合物，具有对内源聚合酶（如聚合酶α和聚合酶γ）的抑制活性。本公开进一步提供了用于治疗过度增殖性疾病或疾病的用途，例如良性或恶性肿瘤，更具体地是对聚合酶α和聚合酶γ抑制敏感的癌症。